Sangamo Therapeutics (SGMOQ) Long-Term Investments (2012 - 2023)

Sangamo Therapeutics' Long-Term Investments history runs 12 years deep, the most recent figure standing at $39.0 million for Q2 2023.

• On a quarterly basis, Long-Term Investments fell 18.62% year-over-year to $39.0 million in Q2 2023; TTM through Jun 2023 was $39.0 million, a 18.62% decrease from a year earlier, with the FY2022 full-year figure at $29.8 million, down 66.15% from the prior year.
• Long-Term Investments climbed to $39.0 million in Q2 2023 per SGMOQ's latest filing, from $35.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $95.6 million in Q3 2021 and bottomed at $5.0 million in Q1 2020.
• The 5-year median for Long-Term Investments is $44.1 million (2020), against an average of $45.7 million.
• Across the five-year window, Long-Term Investments sank 75.28% in 2019 and soared 748.62% in 2021, its largest moves.
• Year by year, Long-Term Investments stood at $21.8 million in 2019, then surged by 131.45% to $50.5 million in 2020, then soared by 74.49% to $88.2 million in 2021, then sank by 66.15% to $29.8 million in 2022, then soared by 30.8% to $39.0 million in 2023.
• Per Business Quant, the three latest SGMOQ Long-Term Investments figures stand at $39.0 million (Q2 2023), $35.6 million (Q1 2023), and $29.8 million (Q4 2022).